Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15211577 | 0.75 | PDXK (0.46) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16580713 | 0.74 | PDXK (0.48) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1355444 | 0.72 | MEN1 (0.46) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23269419 | 0.67 | PDXK (0.42) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7934947 | 0.67 | CYP1A2 (0.39) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7934952 | 0.66 | KDM4E (0.39) | KDM4EALDH1A1LMNA | |
| SCHEMBL4464836 | 0.64 | KMT2A (0.46) | PDXKALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL21713021 | 0.63 | KDM4E (0.46) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30500628 | 0.63 | PDXK (0.50) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16177071 | 0.63 | PDXK (0.50) | PDXKKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589088-B2 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142576-A1 | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | PDXK 17/4885KDM4E 917/4885ALDH1A1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.